NP-001 / Novabio Therapeutics - LARVOL DELTA

Novabio Therapeutics, a China‑based clinical‑stage biotech, announced the successful completion of first patient dosing in a clinical trial for NP001, an autologous polyclonal regulatory T‑cell (Treg) injection for Amyotrophic Lateral Sclerosis (ALS) (flcube.com) - "The patient’s clinical indicators remain stable, and treatment has been well‑tolerated, marking a key milestone for the first‑in‑class cell therapy."

Trial status • Amyotrophic Lateral Sclerosis